24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
IFOSLIEVA 1G is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | IFOSLIEVA 1G |
|---|---|
| Composition | Ifosfamide for Injection with Mesna 1g |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
IFOSLIEVA 1G (Ifosfamide for Injection with Mesna 1g) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
IFOSLIEVA 1 GM (Ifosfamide for Injection with Mesna 1 gm) is a prescription anticancer medicine used in the treatment of various solid tumors and hematological malignancies. It contains Ifosfamide 1 gm, a potent alkylating chemotherapeutic agent, along with Mesna, a uroprotective medicine that helps reduce the risk of bladder toxicity associated with Ifosfamide therapy. This combination is widely used in modern oncology to provide effective cancer treatment while enhancing patient safety.
Cancer occurs when abnormal cells grow uncontrollably and spread to healthy tissues and organs. Ifosfamide works by damaging the DNA of rapidly dividing cancer cells, preventing them from multiplying and spreading. By disrupting the genetic material of cancer cells, the medicine helps slow tumor growth, shrink existing tumors, and improve overall treatment outcomes.
One of the challenges of Ifosfamide treatment is the production of metabolites that may irritate and damage the urinary bladder. To address this concern, Mesna is administered alongside Ifosfamide. Mesna binds to harmful metabolites in the urinary tract and helps protect the bladder from complications such as hemorrhagic cystitis, making treatment safer and more manageable.
IFOSLIEVA 1 GM is commonly prescribed for:
The medicine may be administered alone or in combination with other anticancer medicines depending on the type of cancer, stage of disease, and treatment objectives determined by the oncologist.
Manufactured under stringent pharmaceutical quality standards, IFOSLIEVA 1 GM is designed to provide consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals in hospitals, oncology centers, and specialized cancer treatment facilities.
Patients receiving Ifosfamide therapy generally require routine blood tests, kidney function assessments, liver function evaluations, urine analysis, and regular clinical monitoring to ensure treatment effectiveness and patient safety.
Due to its broad-spectrum anticancer activity and established role in chemotherapy protocols, IFOSLIEVA 1 GM remains an important medicine in comprehensive cancer care worldwide.
IFOSLIEVA 1 GM (Ifosfamide for Injection with Mesna 1 gm) is primarily used for the treatment and management of various cancers.
The medicine is widely used in the treatment of sarcomas affecting muscles, connective tissues, and other soft tissues.
Doctors may prescribe Ifosfamide as part of chemotherapy protocols for bone cancers.
The medicine may be included in treatment regimens for advanced or recurrent testicular cancer.
IFOSLIEVA may be used in selected ovarian cancer treatment programs.
The medicine may form part of specialized chemotherapy strategies for cervical cancer management.
Certain lung cancer treatment protocols may include Ifosfamide-based therapy.
The medicine may be used in selected lymphoma treatment regimens.
Ifosfamide is frequently administered alongside other anticancer medicines to improve treatment outcomes.
Ifosfamide belongs to a class of medicines known as Alkylating Agents.
IFOSLIEVA works by:
Mesna works simultaneously to:
This combination helps deliver effective cancer therapy while minimizing bladder-related complications.
Like all chemotherapy medicines, IFOSLIEVA 1 GM may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Patients may experience mild to moderate nausea during treatment.
Episodes of vomiting may occur after administration.
Weakness and tiredness are commonly reported.
Temporary hair thinning or hair loss may occur.
Reduced appetite may affect nutritional intake.
Some patients may experience dizziness or lightheadedness.
Mild fever may develop during therapy.
Pain, redness, or irritation at the injection site may occur.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of IFOSLIEVA 1 GM (Ifosfamide for Injection with Mesna 1 gm) should always be determined by a qualified oncologist or healthcare professional.
Different cancers require different treatment schedules and protocols.
Dosage is commonly calculated according to body size.
Kidney health plays an important role in treatment planning.
Laboratory test results help determine treatment suitability.
Doctors may adjust therapy based on effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is used for the treatment of various cancers including soft tissue sarcoma, bone sarcoma, testicular cancer, ovarian cancer, cervical cancer, and certain lymphomas.
Ifosfamide is an alkylating chemotherapy medicine that damages cancer cell DNA and helps prevent cancer growth and spread.
Mesna helps protect the bladder from harmful metabolites produced during Ifosfamide treatment and reduces the risk of urinary complications such as hemorrhagic cystitis.
Yes, it is a chemotherapy medicine commonly used in oncology treatment protocols.
Yes, the medicine may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Adequate hydration helps support kidney function and assists in reducing treatment-related urinary complications.
Yes, doctors typically recommend blood tests, kidney function assessments, urine monitoring, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and specialized cancer treatment.